share_log

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga ·  Mar 26 21:05

Gainers

  • Stoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press release, Q4 earnings came out yesterday.
  • OpGen (NASDAQ:OPGN) shares moved upwards by 77.6% to $0.84. The market value of their outstanding shares is at $8.4 million.
  • ABVC BioPharma (NASDAQ:ABVC) stock increased by 45.71% to $1.53. The market value of their outstanding shares is at $16.1 million.
  • Mesoblast (NASDAQ:MESO) shares moved upwards by 32.27% to $2.91. The market value of their outstanding shares is at $295.3 million.
  • Praxis Precision Medicine (NASDAQ:PRAX) shares increased by 21.38% to $61.3. The market value of their outstanding shares is at $811.5 million.
  • Sutro Biopharma (NASDAQ:STRO) stock moved upwards by 18.96% to $3.89. The company's market cap stands at $237.1 million. The company's, Q4 earnings came out yesterday.

Losers

  • NeuBase Therapeutics (NASDAQ:NBSE) stock decreased by 55.0% to $0.45 during Tuesday's pre-market session. The company's market cap stands at $1.6 million.
  • Tivic Health Systems (NASDAQ:TIVC) shares fell 14.49% to $1.24. The company's market cap stands at $1.8 million. The company's, Q4 earnings came out yesterday.
  • bluebird bio (NASDAQ:BLUE) shares fell 12.51% to $1.19. The company's market cap stands at $229.3 million. As per the press release, Q4 earnings came out today.
  • BioLine Rx (NASDAQ:BLRX) stock declined by 11.54% to $1.15. The market value of their outstanding shares is at $83.3 million. The company's, Q4 earnings came out today.
  • iSpecimen (NASDAQ:ISPC) stock fell 8.48% to $0.23. The market value of their outstanding shares is at $2.0 million.
  • IMAC Hldgs (NASDAQ:BACK) stock decreased by 8.27% to $2.22. The company's market cap stands at $2.5 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment